Table 3.

Multivariate analysis of 3‐year OS and PFS in patients with NSCLC

	OS		PFS
	hr (95% CI)	P	hr (95% CI)	P
Age
≥ 55	0.599 (0.321−1.118)	0.108	0.581 (0.318−1.063)	0.078
< 55	1.000 (Ref.)		1.000 (Ref.)
Gender
Men	0.600 (0.296−1.215)	0.156	0.639 (0.317−1.286)	0.209
Women	1.000 (Ref.)		1.000 (Ref.)
Smoking
Yes	0.968 (0.418−2.245)	0.940	0.910 (0.399−2.076)	0.823
No	1.000 (Ref.)		1.000 (Ref.)
Differentiation
Moderate + well	1.182 (0.686−2.035)	0.547	1.044 (0.614−1.774)	0.874
Low	1.000 (Ref.)		1.000 (Ref.)
Lymph node metastasis
Presence (N1 + N2)	0.173 (0.097−0.310)	0.000	0.181 (0.103−0.319)	0.000
Absence (N0)	1.000 (Ref.)		1.000 (Ref.)
T stage
T3	1.398 (0.706−2.768)	0.336	1.352 (0.692−2.642)	0.378
T2	2.187 (1.201−3.981)	0.011	1.756 (0.975−3.165)	0.061
T1	1.000 (Ref.)		1.000 (Ref.)
T1	0.715 (0.361−1.416)	0.336	0.740 (0.379−1.446)	0.378
T2	1.564 (0.712−3.434)	0.265	1.299 (0.601−2.811)	0.506
T3	1.000 (Ref.)		1.000 (Ref.)
LVD
High	0.478 (0.250−0.912)	0.025	0.431 (0.232−0.800)	0.008
Low	1.000 (Ref.)		1.000 (Ref.)
MVD
High	0.397 (0.210−0.753)	0.005	0.513 (0.284−0.928)	0.027
Low	1.000 (Ref.)		1.000 (Ref.)
IL‐35
High	0.351 (0.186−0.663)	0.001	0.415 (0.224−0.766)	0.005
Low	1.000 (Ref.)		1.000 (Ref.)

CI, confidence interval; IL‐35, interleukin‐35; LVD, lymphatic vessel density; MVD, microvessel density; NSCLC, non‐small cell lung cancer; OS, overall survival; PFS, progression‐free survival.